Navigation Links
Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
Date:11/1/2011

NEW YORK, Nov. 1, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease, today announced that a conference call will be held on Thursday, November 3, 2011 at 8:30 a.m. EDT to discuss results for the third quarter ended September 30, 2011 and a business outlook for the remainder of 2011. Ron Bentsur, Chief Executive Officer of Keryx, will host the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

Keryx will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SP
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... N.C. , April 24, 2015  New ... ability of consumers to educate themselves about products ... the tools and techniques available to market researchers ... the changing consumer marketplace, it,s imperative that organizations ... to better identify market opportunities, niches and growth ...
(Date:4/24/2015)... 24, 2015   Vestagen Technical Textiles, Inc. ... , has recently received two notable innovation awards. The ... that recognizes innovations with potential to create a positive ... in New York City , VESTEX ... "Protection & Safety" category. The awards honor excellence in ...
(Date:4/24/2015)... Boston Scientific Corporation (NYSE: BSX ) is ... Annual Healthcare Conference on May 6 in Boston ... president and chief financial officer, and Susie Lisa , ... and answer session regarding the company with the host analyst ... of the presentation and question and answer session will be ...
Breaking Medicine Technology:Pharmaceutical Industry Using New Technologies to Adjust Their Marketing and Research Approaches for Consumers 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3Boston Scientific To Participate In The Deutsche Bank 40th Annual Healthcare Conference 2
... -- La Jolla,Pharmaceutical Company today announced updated interim ... Riquent(R) (abetimus,sodium), its drug candidate for systemic lupus ... previous,conclusion that there is a definitive and significant ... 900 mg doses of Riquent compared,with placebo (p=0.0001). ...
... N.J., March 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corporation's ... a potent payload in antibody conjugates for ... the Handbook of Therapeutic,Antibodies. , In a ... Susanna,Rybak, Ph.D. summarizes preclinical research indicating that ...
Cached Medicine Technology:La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 2La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 3La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 4La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 5La Jolla Pharmaceutical Provides Update on Interim Antibody Results,From Riquent Lupus Phase 3 Trial 6Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
(Date:4/25/2015)... ME (PRWEB) April 26, 2015 ... Canadian based integrative healthcare event. The Integrative Healthcare ... place October 23-24, 2015 at the Sheraton Parkway ... Symposium Canada is one of the most anticipated ... clinically relevant, evidenced-based CME program. The event aims ...
(Date:4/25/2015)... April 25, 2015 The federal ... mesh lawsuits filed against C.R. Bard, Inc. continues ... Southern District of West Virginia. According to a ... was convened that day, after certain defendants submitted ... Complaint. The Order directed that any Preliminary Motions ...
(Date:4/25/2015)... Illinois (PRWEB) April 25, 2015 ... enrichment and wellness, management and operations, and sales ... Meeting and Exhibition scheduled to be held from ... , LeadingAge Illinois is the largest eldercare association ... providers of services for older adults, including senior ...
(Date:4/25/2015)... April 25, 2015 For thirteen years, the ... income protection education event in the nation! This year, on ... Plus Group, US to take DI Day on the road ... G. Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer ... Day reflects on the change by stating, "The first Twin ...
(Date:4/24/2015)... Foothill Ranch, California (PRWEB) April 24, 2015 ... that has a wide range of capabilities and services ... etc. , Ryadon's Quantity Discount Program will be ... ) as follows: , Order 4-19: Receive 10% discount ... Can Benefit by Using the Drawer Slides Products, ...
Breaking Medicine News(10 mins):Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... from the University of Hull has told the British Psychological ... eating chocolate, lazing in front of the television, or going ... could make them more susceptible to disease.Those on the other ... to fight off infection.// ,Researchers asked 30 students ...
... a new gel, which works in a similar way to ... stomach each day, is being tested in four countries world-wide.For ... popping the contraceptive pill. But now there's a new option ... Association says "The gel is like any other gel, but ...
... in the devastated NewYork of America nor in the Afghanistan! It ... And who are the warring parties? They are the pharmaceutical industry ... Chemists Association. The latter is a member body of over 5,000 ... R Shah. // ,It is a classic case of ...
... Researchers in the US have found that genes contribute ... smoking. Chronic obstructive pulmonary disease (COPD), the name given ... because it leads to increasing shortness of breath. It's ... is a major cause of the problem.// ...
... the brain helps people recognise themselves in a picture, ... Deaconess Medical Center in Boston report their findings in ... a growing body of evidence that demonstrates the right ... self-awareness may provide unique insights into consciousness and doctors ...
... People who drink and smoke have to drink more ... greater risk of damage to their brains, livers and hearts, ... reduces blood alcohol levels in rats, which are considered a ... they will end up drinking more alcohol to get an ...
Cached Medicine News:Health News:The right is responsible 2
Straight shafts 4 mm platform. Wide serrated handle with dull finish. Platform angled 45 degrees....
Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
Double-ended. 10 mm sickle shaped blade. 27 mm blunt, curved double-edged blade....
Fixed smooth rod which slides on skin. Designated most popular model or size....
Medicine Products: